← Back to Analyst Consensus 
ENGN Hold
enGene Therapeutics Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 9, 2026 | Citizens | reiterate | Market Perform → Market Perform | — | 46% |
| Sep 8, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 18, 2026 | Morgan Stanley | downgrade | Equal-Weight → Underweight | — | 54% |
| Jun 16, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 14, 2026 | UBS | maintain | Neutral → Neutral | — | 54% |
| May 8, 2026 | Citizens | downgrade | Market Outperform → Market Perform | — | 46% |
| May 8, 2026 | Guggenheim | downgrade | Buy → Neutral | — | 52% |
| May 8, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | — | 54% |
| May 8, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 8, 2026 | Piper Sandler | downgrade | Overweight → Neutral | — | 54% |
| Apr 13, 2026 | WBB Securities | initiate | — → Buy | — | — |
| Mar 11, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Mar 9, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Nov 12, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $19 | 54% |
| Nov 12, 2025 | Oppenheimer | reiterate | Outperform → Outperform | $33 | 52% |
| Nov 12, 2025 | UBS | maintain | Neutral → Neutral | $10 | 54% |
| Nov 12, 2025 | Citizens | maintain | Market Outperform → Market Outperform | $21 | 46% |
| Sep 12, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $18 | 54% |
| Sep 12, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Sep 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Apr 29, 2025 | JMP Securities | reiterate | Market Outperform → Market Outperform | $18 | 53% |
| Mar 11, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $34 | 54% |
| Mar 11, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Feb 18, 2025 | Piper Sandler | initiate | — → Overweight | $26 | 54% |
| Feb 14, 2025 | UBS | downgrade | Buy → Neutral | $7 | 54% |
| Dec 23, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $18 | 53% |
| Dec 23, 2024 | HC Wainwright & Co. | initiate | — → Buy | $25 | 44% |
| Dec 6, 2024 | JMP Securities | reiterate | Market Outperform → Market Outperform | $18 | 53% |
| Nov 27, 2024 | Raymond James | initiate | — → Outperform | $23 | 54% |
| Nov 18, 2024 | JMP Securities | initiate | — → Market Outperform | $18 | 53% |
| Sep 24, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $30 | 52% |
| Sep 11, 2024 | Morgan Stanley | maintain | Overweight → Overweight | $40 | 54% |
| Aug 28, 2024 | Oppenheimer | initiate | — → Outperform | $30 | 52% |
| Apr 22, 2024 | Wells Fargo | initiate | — → Overweight | $30 | 54% |
| Apr 15, 2024 | Guggenheim | initiate | — → Buy | $34 | 52% |
| Mar 28, 2024 | UBS | initiate | — → Buy | $37 | 54% |
| Mar 8, 2024 | Morgan Stanley | initiate | — → Overweight | $40 | 54% |
Price Target Trend
Apr 22, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days